{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:19:45Z","timestamp":1787779185963,"version":"build-2784847793"},"reference-count":22,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Diabetes"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The clinical use of antidiabetic drugs (ADDs) has gained prominent public visibility due to the Food and Drug Administration (FDA) expansion of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in recent years; these drugs are now widely prescribed for weight loss. This shift is reflected in online public discourse.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to analyze the current online public discourse surrounding ADDs, with an emphasis on perceptions of insulin versus noninsulin therapies and the increasing prominence of weight loss\u2013associated medications.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a retrospective analysis of 23,580 English-language posts from the United States in 2023, using Boolean keyword searches to examine conversations about insulin-inclusive, with or without weight loss terms, and insulin-exclusive, with or without weight loss terms. We analyzed the volume and sentiment of online conversations regarding ADDs, frequency of drug mentions, proportion of posts by self-identified physicians, and thematic analysis of patient and clinician concerns.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 26,832 initial posts were collected in 2023. After post validation, 23,580 posts remained as the study sample size. Of the 23,580 posts, 4.6% (1087\/23,580) mentioned insulin, and 95.4% (n=22,493) did not mention insulin. Semaglutide-containing drugs such as Ozempic and Mounjaro were the most referenced medications, particularly in weight-loss contexts. Weight loss conversations made up the majority of online posts. Conversations about insulin were marginal compared with conversations that did not mention insulin online. Only 7% to 10% of posts came from self-identified physicians. Key themes included drug accessibility, off-label use for weight management, concerns about supply shortages, insurance coverage, and growing calls for holistic care. Notably, public perspectives favored the dual efficacy of medications like Ozempic in managing diabetes and promoting weight loss.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The discourse on ADDs is dominated by weight loss\u2013oriented therapies, with GLP-1 RAs driving much of the engagement. This surveillance paper illustrates the current state of public health interests around antidiabetic medications associated with weight loss and raises concerns regarding equitable access for patients with diabetes. These findings underscore the need for updated clinical guidance on necessary lifestyle behaviors for antidiabetic medication use and ongoing monitoring of public opinions regarding chronic disease management medications.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/87590","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:55:06Z","timestamp":1780275306000},"page":"e87590-e87590","source":"Crossref","is-referenced-by-count":0,"title":["Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis"],"prefix":"10.2196","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9198-2460","authenticated-orcid":false,"given":"Chloe","family":"Stallion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4522-0811","authenticated-orcid":false,"given":"Tamkeen","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6350-2436","authenticated-orcid":false,"given":"Christian","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5846-7152","authenticated-orcid":false,"given":"Stavros","family":"Tsipas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4245-8207","authenticated-orcid":false,"given":"Gregory","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"R1","unstructured":"National diabetes statistics report. \u2060Centers for Disease Control and Prevention; 2026. URL: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html [Accessed 26-07-2026]"},{"key":"R2","unstructured":"Diabetes - symptoms and causes. Mayo Clinic. URL: https:\/\/www.mayoclinic.org\/diseases-conditions\/diabetes\/symptoms-causes\/syc-20371444 [Accessed 26-07-2026]"},{"key":"R3","unstructured":"Diabetes basics. \u2060Centers for Disease Control and Prevention. URL: https:\/\/www.cdc.gov\/diabetes\/about\/index.html [Accessed 26-07-2026]"},{"key":"R4","unstructured":"Oral & injectable medications for type 2 diabetes. American Diabetes Association. URL: https:\/\/diabetes.org\/health-wellness\/medication\/oral-other-injectable-diabetes-medications [Accessed 26-07-2026]"},{"key":"R5","unstructured":"Drug trials snapshots: MOUNJARO. U.S. Food and Drug Administration. 2023. URL: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-mounjaro [Accessed 26-07-2026]"},{"key":"R6","unstructured":"FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration. URL: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss [Accessed 26-07-2026]"},{"key":"R7","unstructured":"FDA approves new medication for chronic weight management. U.S. Food and Drug Administration. 2023. URL: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management [Accessed 26-07-2026]"},{"key":"R8","unstructured":"FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. U.S. Food and Drug Administration. 2024. URL: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or [Accessed 26-07-2026]"},{"key":"R9","unstructured":"Glass R Foster E . New demand in an old market. IQVIA. 2023. URL: https:\/\/www.iqvia.com\/locations\/united-states\/blogs\/2023\/08\/new-demand-in-an-old-market [Accessed 26-07-2026]"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/asj\/sjad211","article-title":"Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis","volume":"44","author":"Han","journal-title":"Aesthet Surg J"},{"issue":"9","key":"R11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","journal-title":"JAMA Intern Med"},{"issue":"8","key":"R12","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.2026","article-title":"Prescription fills for semaglutide products by payment method","volume":"5","author":"Scannell","journal-title":"JAMA Health Forum"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.2196\/24681","article-title":"Public perspectives on anti-diabetic drugs: exploratory analysis of Twitter posts","volume":"6","author":"Golder","journal-title":"JMIR Diabetes"},{"key":"R14","unstructured":"Shmerling RH . What happens when a drug goes viral? Harvard Health Publishing. 2023. URL: https:\/\/www.health.harvard.edu\/blog\/what-happens-when-a-drug-goes-viral-202302212892 [Accessed 26-07-2026]"},{"issue":"4","key":"R15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2964","article-title":"Spending on glucagon-like peptide-1 receptor agonists among US adults","volume":"8","author":"Tsipas","journal-title":"JAMA Netw Open"},{"issue":"15","key":"R16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.043137","article-title":"State-level variation in glucagon-like peptide-1 receptor agonists fills and spending by obesity prevalence, 2023","volume":"14","author":"Khan","journal-title":"J Am Heart Assoc"},{"key":"R17","unstructured":"Automated sentiment analysis (ASA). Ipsos. URL: https:\/\/resources.ipsos.com\/rs\/297-CXJ-795\/images\/Synthesio%27s%20Automated%20Sentiment%20Analysis%20Model.pdf [Accessed 26-07-2026]"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133124000306","article-title":"The prevalence and consequences of support for off-label Ozempic prescriptions","author":"Callaghan","journal-title":"Health Econ Policy Law"},{"key":"R19","unstructured":"Shmerling RH . Is metformin a wonder drug? Harvard Health Publishing. 2024. URL: https:\/\/www.health.harvard.edu\/blog\/is-metformin-a-wonder-drug-202109292605 [Accessed 26-07-2026]"},{"key":"R20","unstructured":"Dapagliflozin tablets. Cleveland Clinic. URL: https:\/\/my.clevelandclinic.org\/health\/drugs\/19382-dapagliflozin-tablets [Accessed 26-07-2026]"},{"issue":"9","key":"R21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3949\/ccjm.90a.22096","article-title":"Should I consider metformin therapy for weight loss in patients with obesity but without diabetes?","volume":"90","author":"Rodriguez","journal-title":"Cleve Clin J Med"},{"key":"R22","unstructured":"Middleton J . Semaglutide shortage highlights inequities in diabetic medication access. American Family Physician. 2023. URL: https:\/\/www.aafp.org\/pubs\/afp\/afp-community-blog\/entry\/semaglutide-shortage-highlights-inequities-in-diabetic-medication-access.html [Accessed 26-07-2026]"}],"container-title":["JMIR Diabetes"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:42:07Z","timestamp":1787776927000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetes.jmir.org\/2026\/1\/e87590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2196\/87590","relation":{},"ISSN":["2371-4379"],"issn-type":[{"value":"2371-4379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"v11i1e87590"}}